|
Press Releases |
|
|
|
Wednesday, September 5, 2018 |
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
Friday, July 27, 2018 |
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
Friday, June 22, 2018 |
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
Wednesday, June 6, 2018 |
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
Friday, May 4, 2018 |
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
Wednesday, April 18, 2018 |
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
Wednesday, April 11, 2018 |
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
Friday, March 30, 2018 |
|
Nanobiotix 2017 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
Monday, January 22, 2018 |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
Thursday, January 11, 2018 |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Global News and Publishing Platform Gnomi Launches Paid Journalism Program
May 13, 2024 23:15 HKT/SGT
|
|
|
Creation Business Consultants Expands Presence with New Office in Hong Kong
May 13, 2024 20:20 HKT/SGT
|
|
|
$9.25 Million in Investments Committed to Start-ups during FinTech World Cup at Dubai FinTech Summit
May 13, 2024 19:58 HKT/SGT
|
|
|
富士通、スーパーコンピュータ「富岳」の世界ランキング結果を発表
May 13, 2024 19:00: JST
|
|
|
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
|
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 13, 2024 16:00 HKT/SGT
|
|
|
Creation Business Consultants Expands Presence with New Office in Hong Kong
May 13, 2024 15:30 HKT/SGT
|
|
|
Thailand: Ivy launches plum and tamarind juice drinks in SIG XSlimBloc carton packs
May 13, 2024 15:00 HKT/SGT
|
|
|
3rd Annual Clean Power & New Energy 2024
May 13, 2024 14:03 HKT/SGT
|
|
|
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
|
|
|
日清食品公布2024年首季度业绩
May 13, 2024 13:00 HKT/SGT
|
|
|
日清食品公布2024年首季度業績
May 13, 2024 12:57 HKT/SGT
|
|
|
Spa points haul for TOYOTA GAZOO Racing
May 13, 2024 13:56 JST
|
|
|
Nissin Foods Announces 2024 Q1 Financial Results
May 13, 2024 12:52 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|